| Literature DB >> 30333789 |
Lijuan Cheng1, Daniela Cortese2, Martin M Monti3,4, Fuyan Wang1, Francesco Riganello2, Francesco Arcuri2, Haibo Di1, Caroline Schnakers5.
Abstract
Objectives: Considering sensory stimulation programs (SSP) as a treatment for disorders of consciousness is still debated today. Previous studies investigating its efficacy were affected by various biases among which small sample size and spontaneous recovery. In this study, treatment-related changes were assessed using time-series design in patients with disorders of consciousness (i.e., vegetative state-VS and minimally conscious state-MCS).Entities:
Keywords: brain injuries; consciousness; minimally conscious state; persistent vegetative state; sensory stimulation
Year: 2018 PMID: 30333789 PMCID: PMC6176776 DOI: 10.3389/fneur.2018.00826
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic data for minimally conscious (MCS) and vegetative (VS) patients.
| MCS 1 | Traumatic | 4.8 | 13 | 2 | 3 | 5 | 1 | 0 | 2 |
| MCS 2 | Traumatic | 3.2 | 10 | 2 | 3 | 2 | 1 | 0 | 2 |
| MCS 3 | Traumatic | 4.48 | 10 | 0 | 3 | 5 | 0 | 0 | 2 |
| MCS 4 | Stroke | 2.87 | 13 | 2 | 3 | 4 | 2 | 0 | 2 |
| MCS 5 | Stroke | 2.93 | 10 | 2 | 3 | 2 | 1 | 0 | 2 |
| MCS 6 | Traumatic | 2.93 | 9 | 2 | 3 | 2 | 1 | 0 | 1 |
| MCS 7 | Stroke | 2.91 | 15 | 4 | 5 | 2 | 1 | 1 | 2 |
| MCS 8 | Anoxic | 1.04 | 19 | 4 | 5 | 5 | 2 | 1 | 2 |
| MCS 9 | Traumatic | 2.4 | 10 | 2 | 3 | 2 | 1 | 0 | 2 |
| MCS 10 | Traumatic | 5.52 | 13 | 2 | 3 | 5 | 1 | 0 | 2 |
| MCS 11 | Hemorrhage | 10.07 | 9 | 1 | 3 | 2 | 1 | 0 | 2 |
| MCS 12 | Stroke | 3.53 | 13 | 3 | 1 | 5 | 2 | 0 | 2 |
| MCS 13 | Traumatic | 1.27 | 9 | 2 | 1 | 2 | 2 | 0 | 2 |
| MCS 14 | Traumatic | 5.47 | 8 | 2 | 2 | 2 | 0 | 0 | 2 |
| MCS 15 | Traumatic | 11.6 | 14 | 3 | 4 | 4 | 1 | 0 | 2 |
| MCS 16 | Traumatic | 6.9 | 5 | 0 | 0 | 4 | 1 | 0 | 0 |
| MCS 17 | Traumatic | 2.19 | 11 | 2 | 3 | 2 | 2 | 0 | 2 |
| MCS 18 | Anoxic | 2.42 | 12 | 1 | 3 | 5 | 1 | 0 | 2 |
| VS 1 | Traumatic | 3.95 | 8 | 1 | 1 | 2 | 2 | 0 | 2 |
| VS 2 | Traumatic | 1.45 | 7 | 1 | 1 | 2 | 1 | 0 | 2 |
| VS 3 | Hemorrhage | 1.09 | 6 | 2 | 0 | 2 | 1 | 0 | 1 |
| VS 4 | Hemorrhage | 1.81 | 7 | 2 | 0 | 2 | 1 | 0 | 2 |
| VS 5 | Traumatic | 7.23 | 6 | 0 | 0 | 2 | 2 | 0 | 2 |
| VS 6 | Metabolic | 5.36 | 7 | 2 | 0 | 2 | 1 | 0 | 2 |
| VS 7 | Anoxic | 3.77 | 7 | 1 | 1 | 2 | 2 | 0 | 1 |
| VS 8 | Stroke | 1.28 | 7 | 1 | 0 | 2 | 2 | 0 | 2 |
| VS 9 | Traumatic | 1.33 | 7 | 1 | 1 | 2 | 1 | 0 | 2 |
| VS 10 | Anoxic | 1.37 | 8 | 2 | 1 | 2 | 1 | 0 | 2 |
| VS 11 | Anoxic | 10.7 | 7 | 1 | 0 | 2 | 2 | 0 | 2 |
TSI, Time Since Injury (y = years/m = months); CRS-R, total scores for the Coma Recovery Scale-Revised (AF, Auditory Function; VF, Visual Function; MF, Motor Function; OF, Oromotor Function; C, communication; Ar, Arousal). The highest CRS-R total scores (and its subscores) on the first A phase (baseline) are mentioned.
Figure 1Changes in CRS-R total scores. This figure illustrates the mean (bars = 95% confidence intervals) of the CRS-R total scores on treatment (dark gray) vs. off treatment (light gray) for both vegetative (VS) and minimally conscious (MCS) groups (A) but also within each group, separately (B). Asterisks indicate significant results (p < 0.05).
Results for the Wilcoxon tests performed to compare CRS-R subscores (average ± standard deviation) during A phases and B phases for both VS and MCS groups but also within each group, separately.
| Auditory | 1.33 ± 0.71 | 1.35 ± 0.80 | 0.95 |
| Visual | 1.82 ± 1.39 | 1.84 ± 1.35 | 0.64 |
| Motor | 2.51 ± 1.11 | 2.56 ± 1.19 | 0.57 |
| Oromotor | 1.20 ± 0.38 | 1.34 ± 0.41 | 0.006* |
| Communication | 0.04 ± 0.16 | 0.08 ± 0.32 | 0.18 |
| Arousal | 1.74 ± 0.26 | 1.83 ± 0.19 | 0.005* |
| Auditory | 1.49 ± 0.83 | 1.60 ± 0.88 | 0.30 |
| Visual | 2.63 ± 1.12 | 2.60 ± 1.08 | 0.97 |
| Motor | 2.94 ± 1.23 | 3.03 ± 1.28 | 0.36 |
| Oromotor | 1.18 ± 0.45 | 1.33 ± 0.47 | 0.04* |
| Communication | 0.07 ± 0.20 | 0.13 ± 0.40 | 0.18 |
| Arousal | 1.82 ± 0.26 | 1.91 ± 0.17 | 0.03* |
| Auditory | 1.07 ± 0.36 | 0.95 ± 0.43 | 0.08 |
| Visual | 0.49 ± 0.37 | 0.60 ± 0.62 | 0.39 |
| Motor | 1.82 ± 0.17 | 1.78 ± 0.35 | 0.68 |
| Oromotor | 1.21 ± 0.24 | 1.36 ± 0.33 | 0.07 |
| Communication | 0 ± 0 | 0 ± 0 | 1 |
| Arousal | 1.62 ± 0.21 | 1.7 ± 0.14 | 0.08 |
Significant results are indicated by an asterisk (p < 0.05).
Figure 2Brain areas with treatment-related metabolic changes. The left side of (A) illustrates, at the group level, areas with treatment-related metabolic changes which include the right middle frontal gyrus, the right superior temporal gyrus as well as the bilateral ventro-anterior thalamic nucleus (L = left, R = right) (p < 0.005 voxel-wise uncorrected). On the right side of (A), z-scores for each activated area are also reported at each phase (ABAB) for patients MCS 7, MCS 8, and VS 11. (B) Shows the CRS-R total scores on the last week of each phase (ABAB) for patients MCS 7, MCS 8, and VS 11.